Hypolipidemic effects of chitosan and its derivatives in hyperlipidemic rats induced by a high-fat diet

Food and Nutrition Research

Volumn 60, Issue , 2016, Pages

  Pan, Haitao ^a   Yang, Qingyun ^a   Huang, Guidong ^a   Ding, Chen ^a   Cao, Peiqiu ^a   Huang, Lanlan ^a   Xiao, Tiancun ^b,c   Guo, Jiao ^a   Su, Zhengquan ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Guangzhou Boxabio Ltd D 106 Guangzhou International Business Incubator   (China)

Author keywords

Chitosan; Chitosan oligosaccharides; High fat diet; Hypolipidemic effect; PPAR

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; CHITOSAN; CHITOSAN DERIVATIVE; CHITOSAN OLIGOSACCHARIDE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIMVASTATIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; FOOD INTAKE; HISTOLOGY; HYPERLIPIDEMIA; HYPOLIPIDEMIC EFFECT; LIPID DIET; LIPID METABOLISM; LIVER; LOW DRUG DOSE; MALE; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WEIGHT GAIN;

EID: 84979297317     PISSN: 16546628     EISSN: None     Source Type: Journal    
DOI: 10.3402/fnr.v60.31137     Document Type: Article

References (35)

1. Navar-Boggan AM, Peterson ED, D'Agostino RB, Sr., Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation 2015; 131: 4518.
2. Ahmad S, Beg ZH. Hypolipidemic and antioxidant activities of thymoquinone and limonene in atherogenic suspension fed rats. Food Chem 2013; 138: 111624.
3. Zhang HL, Tao Y, Guo J, Hu YM, Su ZQ. Hypolipidemic effects of chitosan nanoparticles in hyperlipidemia rats induced by high fat diet. Int Immunopharmacol 2011; 11: 45761.
4. Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav 2014; 130: 15769.
5. Zhang HL, Zhong XB, Tao Y, Wu SH, Su ZQ. Effects of chitosan and water-soluble chitosan micro- and nanoparticles in obese rats fed a high-fat diet. Int J Nanomed 2012; 7: 406976.
6. Tao Y, Zhang HL, Hu YM, Wan S, Su ZQ. Preparation of chitosan and water-soluble chitosan microspheres via spraydrying method to lower blood lipids in rats fed with high-fat diets. Int J Mol Sci 2013; 14: 417484.
7. Zhang W, Zhang J, Jiang Q, Xia W. The hypolipidemic activity of chitosan nanopowder prepared by ultrafine milling. Carbohydr Polym 2013; 95: 48791.
8. Wang D, Han J, Yu Y, Li X, Wang Y, Tian H, et al. Chitosan oligosaccharide decreases very-low-density lipoprotein triglyceride and increases high-density lipoprotein cholesterol in highfat-diet-fed rats. Exp Biol Med (Maywood) 2011; 236: 10649.
9. Tan S, Gao B, Tao Y, Guo J, Su ZQ. Antiobese effects of capsaicin-chitosan microsphere (CCMS) in obese rats induced by high fat diet. J Agric Food Chem 2014; 62: 186674.
10. Zou P, Yang X, Wang J, Li Y, Yu H, Zhang Y, et al. Advances in characterisation and biological activities of chitosan and chitosan oligosaccharides. Food Chem 2016; 190: 117481.
11. Choi EH, Yang HP, Chun HS. Chitooligosaccharide ameliorates diet-induced obesity in mice and affects adipose gene expression involved in adipogenesis and inflammation. Nutr Res 2012; 32: 21828.
12. Alishahi A, Aider M. Applications of chitosan in the seafood industry and aquaculture: a review. Food Bioprocess Tech 2012; 5: 81730.
13. Shiomi Y, Yamauchi T, Iwabu M, Okada-Iwabu M, Nakayama R, Orikawa Y, et al. A novel peroxisome proliferator-activated receptor (PPAR)alpha agonist and PPARgamma antagonist, Z-551, ameliorates high-fat diet-induced obesity and metabolic disorders in mice.JBiolChem2015;290:1456781.
14. Usuda D, Kanda T. Peroxisome proliferator-activated receptors for hypertension. World J Cardiol 2014; 6: 74454.
15. Kobayashi J, Miyashita K, Nakajima K, Mabuchi H. Hepatic Lipase: a comprehensive view of its role on plasma lipid and lipoprotein metabolism. J Atheroscler Thromb 2015; 22: 100111.
16. Yang P, Subbaiah PV. Regulation of hepatic lipase activity by sphingomyelin in plasma lipoproteins. Biochim Biophys Acta 2015; 1851: 132736.
17. Zong C, Yu Y, Song G, Luo T, Li L, Wang X, et al. Chitosan oligosaccharides promote reverse cholesterol transport and expression of scavenger receptor BI and CYP7A1 in mice. Exp Biol Med (Maywood) 2012; 237: 194200.
18. Jull AB, Ni Mhurchu C, Bennett DA, Dunshea-Mooij CA, Rodgers A. Chitosan for overweight or obesity. Cochrane Database Syst Rev 2005; 20(3): CD003892.
19. Xu QY, Liu YH, Zhang Q, Ma B, Yang ZD, Liu L, et al. Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats. Acta Pharmacol Sin 2014; 35: 126573.
20. Chen JK, Yeh CH, Wang LC, Liou TH, Shen CR, Liu CL. Chitosan, the marine functional food, is a potent adsorbent of humic acid. Mar Drugs 2011; 9: 248898.
21. Zhang J, Zhang W, Mamadouba B, Xia W. A comparative study on hypolipidemic activities of high and low molecular weight chitosan in rats. Int J Biol Macromol 2012; 51: 5048.
22. van der Velde AE. Reverse cholesterol transport: from classical view to new insights. World J Gastroenterol 2010; 16: 590815.
23. Xia X, Ma Y, Xing X, Huang C, Li L, Gui G, et al. Antioxidant and hepatoprotective effect of different extracts of guizhencao (herba bidentis bipinnatae) against liver injury in hyperlipidemia rats. J Tradit Chin Med 2013; 33: 51823.
24. Kang MY, Cho SH, Lim YH, Seo JC, Hong YC. Effects of environmental cadmium exposure on liver function in adults. Occup Environ Med 2013; 70: 26873.
25. de Souza Predes F, da Silva Diamante MA, Foglio MA, Camargo Cde A, Aoyama H, Miranda SC, et al. Hepatoprotective effect of Arctium lappa root extract on cadmium toxicity in adult Wistar rats. Eur J Pharmacol 2014; 160: 2507.
26. Kimura F, Hasegawa G, Obayashi H, Adachi T, Hara H, Ohta M, et al. Serum extracellular superoxide dismutase in patients with type 2 diabetes: relationship to the development of micro- and macrovascular complications. Diabetes Care 2003; 26: 124650.
27. Wan A, Xu Q, Sun Y, Li H. Antioxidant activity of high molecular weight chitosan and N,O-quaternized chitosans. J Agric Food Chem 2013; 61: 69218.
28. Jarmila V, Vavrikova E. Chitosan derivatives with antimicrobial, antitumour and antioxidant activities ô A review. Curr Pharm Des 2011; 17: 3596607.
29. Chung MJ, Sung NJ, Park CS, Kweon DK, Mantovani A, Moon TW, et al. Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57 BL/6J mice. Eur J Pharmacol 2008; 578: 15970.
30. Cenarro A, Artieda M, Gonzalvo C, Meriño-Ibarra E, Arístegui R, Gañán A, et al. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. Am Heart J 2005; 150(6): 115462.
31. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 538.
32. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003; 144: 22017.
33. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, et al. Novel Peroxisome Proliferator-Activated Receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 1999; 274: 671825.
34. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 58190.
35. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme a reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385: 35161.